Alexion Pharma (ALXN) Tops Q1 EPS by 51c, Lowers FY20 Guiadnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Reports First Quarter 2020 Results
May 6, 2020 6:30 AM EDT1Q20 total revenues of $1,444.8 million, a 27 percent increase over 1Q19 1Q20 GAAP diluted EPS of $2.50; non-GAAP diluted EPS of $3.22 Received positive CHMP opinion for ULTOMIRIS® (ravulizumab) in atypical hemolytic uremic syndrome (aHUS) in the EU Advanced ULTOMIRIS as standard of care in PNH with more than 67% patient conversion from SOLIRIS® (eculizumab) in U.S., Germany and Japan Further diversified development-stage and commercial-stage portfolios with close of Achillion acquisition and announced agreement to acquire Portola Provided update on COVID-19 related activities and impact
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals,... More
